Health care shares are higher Monday. Bloomberg is reporting that a high school teacher in Tasmania is suing Johnson & Johnson over an implanted hip-replacement device that stopped selling in Australia due to defects. Meanwhile, Mylan Inc. (MYL) is higher, helped by positive news from its subsidiary, Matrix Laboratories. The firm received final approval from the U.S. FDA for its New Drug Application (ANDA) for Gabapentin Capsules, which is the generic version of Pfizer's Neurontin. The drug is used to treat a painful complication of shingles.
From FNNO.com, this is the Financial News Network. I’m Cleo
Stiller-Farrell and this is your Midweek Market Wrap Up. The British
Bankers’ Association, which has the supervisory role of setting the
influential Libor rates, announced that it would be willing to give up
its...
